XML 19 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue Recognition
9 Months Ended
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Revenue Recognition
During the three and nine months ended September 30, 2019, the Company recognized total revenue under collaborative research and development and other agreements of $255,000 and $3.0 million, respectively, from AstraZeneca and $612,000 and $803,000, respectively, from various other contracts. The Company defers revenue when a contract is entered into with a collaborator and cash payments are received prior to satisfaction of the related performance obligation. Of the total revenue recognized during the three and nine months ended September 30, 2019, $41,000 and $256,000, respectively, was in deferred revenue as of December 31, 2018. Of the total revenue recognized during the three and nine months ended September 30, 2018, $316,000 and $1.3 million, respectively, was in deferred revenue as of December 31, 2017. Performance obligations are generally satisfied within 12 months of the initial contract date.